Supplementary materials: Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China' published in the Journal of Comparative Effectiveness Research.Symptomatic medications and duration of treatment in multiple sclerosis (MS) adult patients with walking disability (EDSS [expanded disability status scale] score 4-7)Frequency and duration of rehabilitation therapy in MS adult patients with walking disability (EDSS score 4-7)Healthcare resource utilization in the treatment of MS adult patients with walking disability (EDSS score 4-7)The relationship between walking ability and costsSupplementary Table 1 EQ-5D-5L utilities from the ENHANCE and MOBILE trialObjectives: This study evaluates the cost–effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. Materials & methods: A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. Results: Over a 10-year time horizon, adding PRfampridine to BSC led to 0.15 quality-adjusted life year (QALY) gain and lower costs,with incremental cost–effectiveness ratios of -238,806 Chinese Yuan/QALY and -113,488 Chinese Yuan/QALY from the societal and healthcare perspectives, respectively. Conclusion: Compared with BSC alone, PR-fampridine plus BSC is considered an economically dominant strategy for the treatment of multiple sclerosis-related walking disability in China.

本数据集为发表于《比较有效性研究杂志》的论文《在中国使用长效释放型夫马替定治疗多发性硬化症（MS）患者步行障碍的成本效益分析》的同行评审补充材料。研究内容涵盖多发性硬化症（MS）成年患者（步行障碍，EDSS [扩展残疾状态量表]评分4-7）的症候性药物治疗及治疗持续时间、MS成年患者（EDSS评分4-7）的康复治疗频率及持续时间、MS成年患者（EDSS评分4-7）治疗中的医疗资源利用情况，以及步行能力与成本之间的关系。补充表1：ENHANCE和MOBILE试验的EQ-5D-5L效用值。研究目标：本项研究评估了在中国，将长效释放型（PR）夫马替定添加至最佳支持治疗（BSC）与仅使用BSC治疗成年多发性硬化症（MS）患者步行障碍的成本效益。研究方法：从社会和医疗保健的角度构建了混合决策树和马尔可夫模型。参数来源于PR夫马替定的临床试验、公开发表资料以及临床专家访谈。研究结果：在10年的时间范围内，将PR夫马替定添加至BSC治疗相较于仅使用BSC治疗，导致了0.15质量调整生命年（QALY）的增益，并降低了成本，从社会和医疗保健的角度看，增量成本效益比分别为-238,806元/ QALY和-113,488元/ QALY。研究结论：与仅使用BSC治疗相比，PR夫马替定联合BSC治疗在中国被视为治疗MS相关步行障碍的经济优势策略。